Document is current
Any future updates will be listed below
-
Authors
Ho, Hsin-Tien
Shih, Yu-Lueng
Huang, Tien-Yu
Fang, Wen-Hui
Liu, Chang-Hsien
Lin, Jung-Chun
Hsiang, Chih-Weim
Chu, Kai-Min
Hsiong, Cheng-Huei
Chen, Guan-Ju
Wu, Yung-En
Hao, Jia-Yu
Liang, Chih-Wen
Hu, Oliver Yoa-Pu https://orcid.org/0000-0002-9055-0270
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03868566 at ClinicalTrials.govDocuments that mention this clinical trial
Mixed active metabolites of the SNP-6 series of novel compounds mitigate metabolic dysfunction-associated steatohepatitis and fibrosis: promising results from pre-clinical and clinical trials
https://doi.org/10.1186/s12967-024-05686-7
-
Funding
Funding for this research was provided by:
Sinew Pharma Inc
- License Information
-
More Information
Article History
Received: 1 May 2024
Accepted: 1 September 2024
First Online: 14 October 2024
Declarations
:
: The study was conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice guidelines from the International Conference on Harmonisation, and local applicable regulatory requirements. All procedures were approved by the institutional review boards/independent ethics committee at the leading site (Tri-Service General Hospital; IRB No.: 1-106-05-062). All patients provided written informed consent prior to screening. All animal husbandry, care, euthanasia, and use procedures followed the guidelines established by the Institutional Animal Care and Use Committees of the National Defense Medical Center (approval number: IACUC-15-309).
: Not applicable.
: The authors declare that they have no competing interests.
